

# Adriaan Vanderstichele

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4303309/publications.pdf>

Version: 2024-02-01

35  
papers

1,627  
citations

430874

18  
h-index

361022

35  
g-index

36  
all docs

36  
docs citations

36  
times ranked

3911  
citing authors

#	ARTICLE	IF	CITATIONS
1	Randomized CLIO/BCOG-ov10 trial of olaparib monotherapy versus physician's choice chemotherapy in relapsed ovarian cancer. <i>Gynecologic Oncology</i> , 2022, 165, 14-22.	1.4	14
2	Nucleosome footprinting in plasma cell-free DNA for the pre-surgical diagnosis of ovarian cancer. <i>Npj Genomic Medicine</i> , 2022, 7, 30.	3.8	4
3	Pan-Cancer Detection and Typing by Mining Patterns in Large Genome-Wide Cell-Free DNA Sequencing Datasets. <i>Clinical Chemistry</i> , 2022, 68, 1164-1176.	3.2	6
4	Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 217-228.	2.5	12
5	High-grade serous tubo-ovarian cancer refined with single-cell RNA sequencing: specific cell subtypes influence survival and determine molecular subtype classification. <i>Genome Medicine</i> , 2021, 13, 111.	8.2	70
6	miR-203 is an independent molecular predictor of prognosis and treatment outcome in ovarian cancer: a multi-institutional study. <i>Carcinogenesis</i> , 2020, 41, 442-451.	2.8	10
7	Ultra-Sensitive TP53 Sequencing for Cancer Detection Reveals Progressive Clonal Selection in Normal Tissue over a Century of Human Lifespan. <i>Cell Reports</i> , 2019, 28, 132-144.e3.	6.4	72
8	Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American Women. <i>Cancer Medicine</i> , 2019, 8, 2503-2513.	2.8	6
9	Myeloid-derived suppressor cells at diagnosis may discriminate between benign and malignant ovarian tumors. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1381-1388.	2.5	17
10	Randomized phase II CLIO study on olaparib monotherapy versus chemotherapy in platinum-resistant ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 5507-5507.	1.6	36
11	Antiangiogenic therapies in ovarian cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2018, 11, 18-26.	0.5	1
12	Genetic overlap between endometriosis and endometrial cancer: evidence from cross-disease genetic correlation and GWAS meta-analyses. <i>Cancer Medicine</i> , 2018, 7, 1978-1987.	2.8	62
13	Immunobiochemical pathways of neopterin formation and tryptophan breakdown via indoleamine 2,3-dioxygenase correlate with circulating tumor cells in ovarian cancer patientsâ€” A study of the OVCAD consortium. <i>Gynecologic Oncology</i> , 2018, 149, 371-380.	1.4	11
14	Uterine and Tubal Lavage for Earlier Cancer Detection Using an Innovative Catheter: A Feasibility and Safety Study. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 1692-1698.	2.5	18
15	Clinical Significance of Organic Anion Transporting Polypeptide Gene Expression in High-Grade Serous Ovarian Cancer. <i>Frontiers in Pharmacology</i> , 2018, 9, 842.	3.5	5
16	Characterisation of tumour microvessel density during progression of high-grade serous ovarian cancer: clinico-pathological impact (an OCTIPS Consortium study).. <i>British Journal of Cancer</i> , 2018, 119, 330-338.	6.4	13
17	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. <i>Cancer Research</i> , 2018, 78, 5419-5430.	0.9	54
18	Identification of nine new susceptibility loci for endometrial cancer. <i>Nature Communications</i> , 2018, 9, 3166.	12.8	178

#	ARTICLE	IF	CITATIONS
19	Diffusely Metastasized Adenocarcinoma Arising in a Mucinous Carcinoid of the Ovary. <i>International Journal of Gynecological Pathology</i> , 2018, 37, 290-295.	1.4	7
20	Clinical significance of the estrogen-modifying enzymes steroid sulfatase and estrogen sulfotransferase in epithelial ovarian cancer. <i>Oncology Letters</i> , 2017, 13, 4047-4054.	1.8	25
21	Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapyâ€“Innovative Models Prolong Survival (OCTIPS) Consortium. <i>European Journal of Cancer</i> , 2017, 79, 214-225.	2.8	29
22	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature Genetics</i> , 2017, 49, 680-691.	21.4	356
23	A Complex Network of Tumor Microenvironment in Human High-Grade Serous Ovarian Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 7621-7632.	7.0	31
24	Genomic signatures as predictive biomarkers of homologous recombination deficiency in ovarian cancer. <i>European Journal of Cancer</i> , 2017, 86, 5-14.	2.8	49
25	Chromosomal Instability in Cell-Free DNA as a Highly Specific Biomarker for Detection of Ovarian Cancer in Women with Adnexal Masses. <i>Clinical Cancer Research</i> , 2017, 23, 2223-2231.	7.0	80
26	Platinum-Based Chemotherapy Induces Methylation Changes in Blood DNA Associated with Overall Survival in Patients with Ovarian Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 2213-2222.	7.0	83
27	No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 420-424.	2.5	3
28	Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. <i>Human Genetics</i> , 2016, 135, 741-756.	3.8	19
29	Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. <i>International Journal of Epidemiology</i> , 2016, 45, 1619-1630.	1.9	111
30	How to Select Neoadjuvant Chemotherapy or Primary Debulking Surgery in Patients With Stage IIIC or IV Ovarian Carcinoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 3827-3828.	1.6	35
31	Combined modality adjuvant therapy for high-risk endometrial cancer. <i>Lancet Oncology</i> , The, 2016, 17, 1029-1030.	10.7	6
32	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breastâ€“ovarian cancer susceptibility locus. <i>Nature Communications</i> , 2016, 7, 12675.	12.8	78
33	Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer. <i>European Journal of Cancer</i> , 2016, 53, 51-64.	2.8	45
34	Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration. <i>Oncotarget</i> , 2016, 7, 72381-72394.	1.8	13
35	Shared genetics underlying epidemiological association between endometriosis and ovarian cancer. <i>Human Molecular Genetics</i> , 2015, 24, 5955-5964.	2.9	68